CER-209 is under clinical development by ABIONYX Pharma and currently in Phase I for Dyslipidemia. According to GlobalData, Phase I drugs for Dyslipidemia have a 68% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CER-209’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CER-209 overview
CER-209 is under development for the treatment of dyslipidemia with low HDL (high-density lipoprotein), atherosclerosis, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis. It is a small molecule administered orally. It targets P2Y13 receptors.
ABIONYX Pharma overview
ABIONYX Pharma (ABIONYX) is a biopharmaceutical company that develops HDL therapies for the treatment of cardiovascular and metabolic diseases. Its therapies include CER-001, a negatively charged lipoprotein particle that finds application atherosclerotic plaque regression, and CER-209, a simulator of HDL receptors. The company develops a portfolio of HDL therapies including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as patients with HDL deficiency, and post-ACS patients. It also develops drugs that increase HDL for patients with a low number of HDL particles to treat atherosclerosis and related metabolic diseases. ABIONYX works in partnership with other research and biotechnology companies for the development of HDL drug delivery products and technologies. The company has a presence across France and the US. ABIONYX is headquartered in Balma, France.
For a complete picture of CER-209’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
